SciClone files Hong Kong IPO
SciClone Pharmaceuticals has filed for an IPO on the Hong Kong Stock Exchange, three years after it was privatized by a consortium led by China-focused health care investment group GL Capital.
The Shanghai-based drug maker is looking to join the list of Chinese biotechs that have gone public since the city began accepting pre-revenue health care companies on the bourse.
Formerly based out of California, SciClone began trading on the Nasdaq in 1992 until its delisting in 2017. The company’s sole proprietary drug, Zadaxin, was expanded to overseas markets in the ’90s. The drug is used as an adjuvant therapy in various cancer types, and as a treatment for infectious diseases such as hepatitis B and C.
China recently listed Zadaxin as a treatment option for Covid-19, and a small study suggested it may reduce the mortality of severe Covid-19 patients.
The Shanghai-based drug maker is looking to join the list of Chinese biotechs that have gone public since the city began accepting pre-revenue health care companies on the bourse.
Formerly based out of California, SciClone began trading on the Nasdaq in 1992 until its delisting in 2017. The company’s sole proprietary drug, Zadaxin, was expanded to overseas markets in the ’90s. The drug is used as an adjuvant therapy in various cancer types, and as a treatment for infectious diseases such as hepatitis B and C.
China recently listed Zadaxin as a treatment option for Covid-19, and a small study suggested it may reduce the mortality of severe Covid-19 patients.
.png)
No hay comentarios:
Publicar un comentario